Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

COMIRNATY® (COVID-19 Vaccine, mRNA) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older. COMIRNATY must be injected intramuscularly only.

Health Canada has authorized the sale of COMIRNATY Original & Omicron BA.4/BA.5 bivalent vaccine with terms and conditions.

COMIRNATY® Original & Omicron BA.4/BA.5 [COVID-19 mRNA Vaccine, Bivalent (Original and Omicron BA.4/BA.5)] is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) in individuals 5 years of age and older. COMIRNATY Original & Omicron BA.4/BA.5 bivalent vaccine must be injected intramuscularly only.

  • Marketing authorization has been issued with Terms and Conditions that need to be met by the Market Authorization Holder to ascertain the continued quality, safety and effectiveness of the vaccine.
  • The safety and effectiveness of a primary vaccination course or booster dose of COMIRNATY Original & Omicron BA.4/BA.5 for individuals 5 years of age and older is inferred from studies which evaluated the primary series and booster vaccination with COMIRNATY and supported by studies of a booster dose of COMIRNATY Original & Omicron BA.4/BA.5 in individuals >5 years of age.

Please review the label carefully to ensure that you select the appropriate vaccine for immunization. Please review the COMIRNATY or the COMIRNATY Original & Omicron BA.4/BA.5, Bivalent Product Monograph for more complete information. Each Product Monograph is available below, at www.pfizer.ca/en/our-products, or www.cvdvaccine.ca.

Comirnaty (COVID-19 Vaccine, mRNA) and Comirnaty Original & Omicron BA.4/BA.5 [bivalent]

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

Comirnaty and Comirnaty Original & Omicron BA.4/BA.5 Quick Finder

Download Product Monograph Note: the information below includes the Part I: Health Professional Information.
Download Product Monograph Note: the information below includes the Part I: Health Professional Information.
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event